Tocotrienol as a Nutritional Supplement in Patients With Advanced Ovarian Cancer

Sponsor
Vejle Hospital
Study ID
NCT02399592
Phase
PHASE2
Status
Completed

Conditions

Eligibility Criteria

Sex
FEMALE
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Bevacizumab — DRUG
    10 mg/kg q3w
  • Tocotrinol — DRUG
    300 mg tid

Study Details

The purpose of this study is to to investigate the effect of tocotrienol as a nutritional supplement in combination with bevacizumab in patients with advanced ovarian cancer.

Key Dates

First listed
Mar 26, 2015
Start date
Mar 31, 2015
Status verified
Feb 2020
Primary completion
Jul 31, 2019
Completion
Jul 31, 2019

Study Design

Enrollment
23 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Bevacizumab and Tocotrienol

Primary Outcome Measure

Fraction of patients without progression after six months of treatment [ Time Frame: 6 months after start of treatment ]

Related Studies